|
|
| (29 intermediate revisions by 5 users not shown) |
| Line 4: |
Line 4: |
| Image = 1151.jpg| | | Image = 1151.jpg| |
| Caption = Dilated Cardiomyopathy: Gross dilated left ventricle with marked endocardial sclerosis <br> <small> [http://www.peir.net Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology] </small>| | | Caption = Dilated Cardiomyopathy: Gross dilated left ventricle with marked endocardial sclerosis <br> <small> [http://www.peir.net Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology] </small>| |
| DiseasesDB = 3066 |
| |
| ICD10 = {{ICD10|I|42|0|i|30}} |
| |
| ICD9 = {{ICD9|425.4}} |
| |
| ICDO = |
| |
| OMIM = 212110 |
| |
| MedlinePlus = 000168 |
| |
| eMedicineSubj = |
| |
| eMedicineTopic = |
| |
| eMedicine_mult = |
| |
| MeshID = D002311 |
| |
| }} | | }} |
| {{Dilated cardiomyopathy}} | | {{Dilated cardiomyopathy}} |
|
| |
|
| {{CMG}}; '''Associate Editor-in-Chief:''' Sachin Shah, M.D.
| | '''For patient information, click [[Dilated cardiomyopathy (patient information)|here]]''' |
|
| |
|
| {{SK}} DCM; congestive cardiomyopathy | | {{CMG}}; {{AE}}{{AIA}}; Sachin Shah, M.D. |
| | |
| | {{SK}} Congestive cardiomyopathy; DCM |
|
| |
|
| ==[[Dilated cardiomyopathy overview|Overview]]== | | ==[[Dilated cardiomyopathy overview|Overview]]== |
|
| |
|
| ==Causes== | | ==[[Dilated cardiomyopathy historical perspective|Historical Perspective]]== |
| | |
| | ==[[Dilated cardiomyopathy pathophysiology|Pathophysiology]]== |
|
| |
|
| ==Clinical Presentation== | | ==[[Dilated cardiomyopathy causes|Causes]]== |
|
| |
|
| ==Diagnosis== | | ==[[Dilated cardiomyopathy differential diagnosis|Differentiating Dilated cardiomyopathy from other Diseases]]== |
| The diagnosis of dilated cardiomyopathy is based on clinical presentation and imaging findings. The most common imaging modality used to diagnose dilated cardiomyopathy is 2D-echocardiography. Echocardiographic findings of dilated cardiomyopathy include dilation of the left ventricle; however, may include dilation of all 4 cardiac chambers, LV (left ventricular) wall thickness usually is normal but given the dilation the LV mass is increased. In addition there is a global reduciton in systolic function. Occasionally there may also be focal wall motion abnormalities even in patients ''without'' flow limiting coronary artery disease.<ref> Mayo Clinic Cardiology. Concise Textbook. Murphy, Joseph G; Lloyd, Margaret A. Mayo Clinic Scientific Press. 2007.</ref>
| |
|
| |
|
| The diagnosis requires a dilated left ventricle and low ejection fraction.
| | ==[[Dilated cardiomyopathy epidemiology and demographics|Epidemiology and Demographics]]== |
|
| |
|
| In terms of determining the etiology a careful history is most instrumental. If the patient has CAD (coronary artery disease) risk factors, known CAD, or angina then a workup for CAD should be undertaken with coronary angiography. A viral prodrome such as viral URI or viral gastroenteritis may make viral myocarditis as a more likely cause. If the patient was exposed to chemotherapy such as anthracyclines then this would be the likely cause. Patients at risk for HIV should undergo testing as HIV can cause a dilated cardiomyopathy. Peripartum cardiomyopathy most often occurs 1 month prior to expected delivery or 5 months after delivery, so recent childbirth is important information. Often by 8 months gestational age pregnancy is physically apparent but it is important to rule out pregnancy in women of childbearing age with dilated cardiomyopathy. Screening questions regarding cocaine or alcohol abuse or other toxin exposure (such as cobalt) should be addressed.
| | ==[[Dilated cardiomyopathy risk factors|Risk Factors]]== |
|
| |
|
| A review of systems is also helpful in regards to connective tissue disease associated dilated cardiomyopathy (which can be related to SLE (systemic lupus erythematosis), rheumatoid arthritis, sarcoidosis, scleroderma, as well as other connective tissue diseases).
| | ==[[Dilated cardiomyopathy screening|Screening]]== |
|
| |
|
| A family history also has a great importance in the diagnosis of dilated cardiomyopathy. It has been suggested that a portion of those patients labeled as "idiopathic" may have a familial form of the disease. The prevalence of this in the population of patients with dilated cardiomyopathy has been estimated as high as 25%.<ref>Ross J Jr. Dilated cardiomyopathy: concepts derived from gene deficient and transgenic animal models. Circ J. 2002;66:219-24. PMID 11922267</ref> The majority of these are thought to be related to autosomal dominant transmission, the remaining are thought to be transimtted in an autosomal recessive and X-linked fashion.<ref>Mestroni L; Rocco C; et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J Am Coll Cardiol 1999 Jul;34(1):181-90.</ref> Mitochondrial inheritance of the disease has also been identified.<ref>Schonberger J, Seidman CE. Many roads lead to a broken heart: the genetics of dilated cardiomyopathy. Am J Hum Genet. 2001;69:249-60. Epub 2001 Jul 6. PMID 11443548</ref>
| | ==[[Dilated cardiomyopathy natural history, complications and prognosis|Natural History, Complications and Prognosis]]== |
|
| |
|
| Pericardial effusion may accompany myocarditis but this finding is not specific. Cardiac MRI as discussed above may be helpful in diagnosing myocarditis. Endomyocardial biopsy as discussed above has low sensitivy and the findings are also notoriously non-specific. The findings on biopsy usually involve findings of inflammation and specific pathogens are unlikely to be identified. There may be an increased yield to using MRI to target endomyocardial biopsy as described above. Viral titiers (serologies) are often unhelpful and not routinely ordered in clinical practice.
| | ==Diagnosis== |
|
| |
|
| ==Prognosis==
| | [[Dilated cardiomyopathy history and symptoms|History and Symptoms]] | [[Dilated cardiomyopathy physical examination|Physical Examination]] | [[Dilated cardiomyopathy laboratory findings|Laboratory Findings]] | [[Dilated cardiomyopathy electrocardiogram|Electrocardiogram]] | [[Dilated cardiomyopathy chest x ray|Chest X-Ray]] | [[Dilated cardiomyopathy CT|CT]] | [[Dilated cardiomyopathy MRI|MRI]] | [[Dilated cardiomyopathy echocardiography|Echocardiography]] | [[Dilated cardiomyopathy other imaging findings|Other Imaging Findings]] | [[Dilated cardiomyopathy genetic testing|Genetic testing]] | [[Dilated cardiomyopathy other diagnostic studies|Other Diagnostic Studies]] |
|
| |
|
| ==Treatment== | | ==Treatment== |
| Death from dilated cardiomyopathy is usually the result of progressive heart failure or arrhythmia. Treatments for dilated cardiomyopathy are targeted towards preventing death and treating symptoms of heart failure. Some medications (such as ACE inhibitors) may help acheive both goals. Initial treatment should focus on the underlying cause of dilated cardiomyopathy if reversible. If for example a patient has dilated cardiomyopathy and three vessel coronary artery disease then revascularization should be an initial step in treatment.
| |
|
| |
| Medications which have a proven survival benefit in systolic heart failure are ACE (angiotensin converting enzyme) inhibitors, ARBs (angiotensin II receptor blockers), beta blockers (carvedilol, bisoprolol and metoprolol succinate are the most well studied), aldosterone antagonists (in severe heart failure) and combination of long acting nitrates and hydralazine. Medications targeted towards symptom relief in systolic heart failure are diuretics and digoxin. Warfarin is also a medication used in systolic heart failure; the benefit of this medication is controversial.
| |
|
| |
| ===ACE inhibitors in dilated cardiomoypathy===
| |
| ACE inhibitors are thought to be useful in dilated cardiomyopathy by not only causing arterial vasodilation and reduction of afterload but also by reduction in levels of angiotensin II, aldosterone, and ADH which may have deleterious remodeling effects on the heart as well as vasoconstriction. ACE inhibitors have been extensively studied in systolic heart failure and have been shown to reduce symptoms, slow the progression of heart failure and reduce mortality in all classes of heart failure. The most profound impact is seen in patients who are most symptomatic as well as those patients who have recently suffered a myocardial infarction. In addition ACE inhibitors have been shown to slow the progression of LV (left ventricular) dilation in systolic heart failure.
| |
|
| |
| The SOLVD-Prevention trial and SAVE trial both are large randomized controlled trials which evaluated patients with asymptomatic systolic heart failure. SOLVD-Prevention examined 4000 patients with an EF < 35% who were asymptomatic and randomized them to enalapril (dose 2.5-20mg daily) or placebo. After an average 3 years follow up there was a significant reduction in heart failure hospitalizations but no difference in mortality. The SAVE (Survival and Ventricular Enlargement) trial studied 2200 patients with an EF < or = to 40% within 3-14 days following an acute myocardial infarction. These patients were given either captopril or placebo and followed for an average of 3.5 years. There was a significant 25% reduciton in myocardial infarction and a significant reduction in death from recurrent MI by 32% in the captopril group.<ref>Circulation, Oct 1994;90:1731-1738.</ref>
| |
|
| |
| The CONSENSUS, SOLVD-Treatment and V-HeFT II trials all examined ACE inhibitors in symptomatic patients with systolic heart failure. The CONSENSUS trial was published in 1987 and studied 250 patients with NYHA class IV heart failure. These patients were randomized to enalapril (dose 2.5mg - 40mg daily) or placebo. After an average follow up of 6 months there was a 40% reduction in mortality in the enalapril group (this persisted to 1 year, at 1 year there was a 31% reduction in mortality in the enalapril group). The reduction in mortality was attributed to a reduction in the death from progressive heart failure, not from a reduction in sudden cardiac death. SOLVD-Treatement and V-HeFT II also showed a reduction in mortality with ACE inhibitors, both of these studies evalauted mainly patients with NYHA class II or III heart failure.<ref>N Engl J Med. 1991 Aug 1;325(5):303-10</ref><ref>N Engl J Med. 1991 Aug 1;325(5):293-302.</ref>
| |
|
| |
| The AIRE and TRACE trials were placebo controlled randomized controlled trials which both evaluated ACE inhibitors (ramipril and trandolapril respectively) in heart failure following a myocardial infarction. Both of these studies also showed a reduction in mortality in the ACE inhibitor arm when compared to placebo. These studies evaluated patients at a minimum of 2 (AIRE) or 3 (TRACE) days following an acute MI.
| |
|
| |
| The CONSENSUS II, ISIS-4, GISSI-3 and SMILE studies all evaluated patients early (within 24 hours) following an acute myocardial infarction. All but the CONSENSUS II study showed a mortality benefit (both short and long term) in the ACE inhibitor arm when compared to placebo.<ref>Lancet. 1995 Mar 18;345(8951):669-85</ref><ref>Lancet. 1994 May 7;343(8906):1115-22</ref><ref>N Engl J Med. 1995 Jan 12;332(2):80-5.</ref>
| |
|
| |
| ===ARBs in dilated cardiomyopathy===
| |
| ARBs have also been extensively studied. There are at least four large trials which support the use of ARBs in systolic heart failure. These include the ELITE, ELITE II, Val-HeFT, and CHARM trials. The ELITE trial randomized 722 patients over the age of 65 with an EF < 40% and NYHA class II-IV heart failure to either an ACEi (captopril) or an ARB (losartan). After a follow up of 48 weeks there was no difference in the primary endpoint (persistent elevations in serum creatinine) however a secondary endpoint of mortality showed a risk reduction of 46% in teh losartan group.<ref>Lancet 1997;349:747-52</ref> This was further evaluated in the ELITE II trial which randomized 3150 patients similar to those in the ELITE trial and again compared captopril and losartan. After a mean follow up of 555 days there was no difference in mortalitity or resuscitated arrest, but losartan was "better tolerated" than captopril (captopril was most often discontinued due to ACEi related cough).<ref>Lancet. 2000;355:1582-1587.</ref> The Val-HeFT trial was a placebo controlled RCT that evaluated studied valsartan use in 5000 patients with heart failure. There was a reduction in the combined endpoint of mortality and morbidity after a mean follow up of 23 months.<ref>N Engl J Med. 2001 Dec 6;345(23):1667-75</ref>
| |
|
| |
| CHARM randomized 7,600 patients to candesartan or placebo. There were 3 subgroups analyzed in this study. CHARM Added showed that there was a reduction in cardiovascular mortality or CHF hospitlization in patients with systolic heart failure (EF < 40%) who were taking candesartan as well as an ACEi when compared to an ACEi alone. The CHARM Alternative subgroup showed that in ACEi intolerant patients with systolic heart failure (EF < 40%) there was a reduction in mortality or CHF hospitalization in patients taking an ARB (candesartan) when compared to placebo. The CHARM Preserved group evaluated patients with heart failure and a preserved ejection fraction and found no difference between candesartan and placebo.<ref>Circulation 2004; 110:2180</ref>
| |
|
| |
| The data is very strongly in favor of using ACEi as first line medications for systolic heart failure, and the addition of ARBs may be helpful. In addition, if patients are intolerant of ACEi there are clear benefits to using ARBs.
| |
|
| |
| ===Beta Blockers in dilated cardiomyopathy===
| |
| Beta blockers have been extensively studied in systolic heart failure. Bisoprolol, metoprolol succinate and carvedilol are the most supported by data. The U.S. Carvedilol study randomized roughly 1000 patients with an EF < 35% to either carvedilol or placebo. The study was stopped early as there was a 65% risk reduction in mortality in the carvedilol group and there was also a reduction in hospitalizations from a cardiac cause.<ref>N Enlg J Med. 1996 May 23;334(21):1349-55.</ref> The MERIT HF trial randomized 4000 patients NYHA II-IV with an EF < 40% to receive either metoprolol succinate ("Toprol XL") at doses 12.5mg daily uptitrated to 200mg daily or placebo. After a mean of 1 year follow up the study was also stopped early as there was a 34% risk reduction in mortality in the metoprolol succinate group. This reduction in mortality was attributed both to a reduction in sudden cardiac death as well as death from heart failure.<ref>Lancet 1999 Jun 12;353(9169):2001-7.</ref> Other large trials of beta blockers in systolic heart failure include CIBIS-II, COPERNICUS, and COMET.
| |
|
| |
| ===Aldosterone antagonists in dilated cardiomyopathy===
| |
| Aldosterone antagonists have been used in systolic heart failure and have been shown to have a mortality benefit. Based on results of the RALES trial aldosterone antagonists are used in patients with systolic dysfunction and NYHA class III or IV heart failure. Hyperkalemia is an important side effect in heart failure patients especially who may have concominant renal disease or may be on an ACE inhibitor and / or an ARB. Spironolactone and epleronone are commonly used aldosterone antagonists. Epleronone is more specific to the mineralocorticoid receptors and spironolactone binds relatively more androgen and progesterone receptos; therefore, spironolactone is more likely to cause endocrine side effects such as gynecomastia in men. The RALES trial randomized 1663 patients with an EF < 35% and severe heart failure to spironolactone (25mg daily) or placebo. The patients were also taking ACEi, loop diuretics and most were taking digoxin. The study was stopped early after a mean of 24 months follow up as there was a 30% risk reduction in mortality noted in the spironolactone group. This reduction in mortality was attributed both to a reduction of progresive heart failure deaths and a reduction in sudden cardiac death.<ref>N Engl J Med. 1999 Sep 2;341(10):709-17.</ref>
| |
|
| |
| ===Long acting nitrate and hydralazine combinations in dilated cardiomyopathy===
| |
| VHeFT-I and VHeFT-II have shown that there is a benefit in morbidity and mortality to long acting nitrates combined with hydralazine in patients with systolic heart failure. This effect is thought to be less robust than ACEi (VHeFT-I compared this combination to an ACEi enalapril and showed a reduction in mortality in the ACEi group). Common practice is to use this combination in patients who are unable to tolerate an ACEi or ARB; such as patients with advanced renal disease.
| |
|
| |
| ===Warfarin in dilated cardiomyopathy===
| |
| As stated above warfarin is a medication that is occasionally used in systolic heart failure and the benefits are controversial. In systolic heart failure and atrial fibrillation there is a more clear benefit in terms of stroke prevention; however, in isolated systolic heart failure the reduction in embolic risk has not been fully elucidated.
| |
|
| |
| ===Diuretics in dilated cardiomyopathy===
| |
| Loop diuretic medications are commonly used for patients with symptoms of heart failure. There has been no clear survival benefit associated with loop diuretics; however, the use of diuretics and a sodium restricted diet are the mainstays of treatment for congestive symptoms.
| |
|
| |
| ===Digoxin in dilated cardiomyopathy===
| |
| Digoxin is sometimes used in systolic heart failure for symptom relief. A survival benefit has not been shown with digoxin use; however, it is useful for symptomatic treatment. There may be more of a role for digoxin in systolic heart failure and atrial fibrillation as digoxin may serve a dual purpose of heart failure symptom relief related to increased ionotropy as well as ventricular rate control related to AV nodal blockade. The RADIANCE trial and The Digoxin Study evaluated digoxin in heart failure patients.
| |
|
| |
| ===N-3 polyunsaturated fatty acids===
| |
| N-3 polyunsaturated fatty acids have also been evaluated by the GISSI-HF group and showed a slight reduction in mortality (from 29% to 27%) at roughly 3 years of follow up.<ref>Tavazzi L; Maggioni AP, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Oct 4;372(9645):1223-30. Epub 2008 Aug 29.</ref>
| |
|
| |
| ==Advanced Therapies==
| |
| In patients with end stage heart failure or hemodynamic compromise vasopressor agents may be helpful. In patients with hemodynamic compromise medications such as dobutamine or dopamine may provide blood pressure support necessary. In addition parental agents such as milrinone (a phosphodiesterase inhibitor- somewhat specific for cardiac and vascular tissue) may be helpful in the short term or for end stage patients. There is no clear survival benefit and most trials with IV phosphodiesterase inhibitors are small trials of end stage heart failure patients. Oral milrinone has been studied and has been shown to increase mortality (as seen in the PROMISE trial).
| |
|
| |
| In patients who have severe heart failure and are refractory to medical therapy cardiac transplantation may be an option (based upon patient characteristics such as age and comorbidities as well as disease characterisitics such as the etiology of dilated cardiomyopathy). As a bridge to cardiac transplantation multiple mechanical devices have been used. The most durable device is the LVAD (left ventricular assist device), certain patient populations not suitable for cardiac transplantation may also undergo LVAD placement by a cardiac surgeon as a "destination LVAD." This may be considered a palliative measure for end-stage heart failure patients. Other devices which may be more limited in the duration of use include the aortic balloon pump, Impella, and the PVAD (peripheral ventricular assist device) one of which is the Tandem Heart.
| |
|
| |
| ===Implantable cardiac defibrillators in dilated cardiomyopathy===
| |
| Implantable cardiac defibrillators (ICDs) have also been extensively studied in systolic heart failure. A survival benefit has also been shown in select patient populations. ICDs are implanted in patients with systolic heart failure for primary prevention of sudden cardiac death. The AHA/ACC (American Heart Association/American College of Cardiology) class I indications for ICDs for primary prevention are: 1. EF < 35% due to prior MI, 40 days post MI, NYHA class II or III. 2. EF < 35% NYHA class II or III non ischemic dilated cardiomyopathy. 3. EF < 30%, prior MI, 40 days post MI, NYHA I. 4. EF < 40%, prior MI, NSVT and inducible VT/VF at EP study.
| |
|
| |
| There are four major studies that have helped shape these indication for an ICD. The MADIT I evaluated NYHA class I to III heart failure patients with an EF < or = to 35%, with NSVT and inducible VT or VF on EP study and randomized 196 patients to ICD versus conventional medical therapy. The patients who received ICDs had improved survival at 5 years. 60% of patients received shocks by 2 years.<ref>N Engl J Med. 1996. Dec 355(26)</ref> The findings from this study are encompassed in the remaining three studies.
| |
|
| |
|
| Madit II randomized 1232 patients who had a prior MI > 1 month prior to enrollment, an EF < or = to 30% to ICD or medical therapy and after a follow up of an average of 20 months there was a survival advantage in the ICD group. The number needed to treat was 18 patients. <ref>N Engl J Med. 2002. Mar 346(12)</ref>
| | [[Dilated cardiomyopathy medical therapy|Medical Therapy]] | [[Dilated cardiomyopathy surgery|Surgery]] | [[Dilated cardiomyopathy primary prevention|Primary Prevention]] | [[Dilated cardiomyopathy secondary prevention|Secondary Prevention]] | [[Dilated cardiomyopathy cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Dilated cardiomyopathy future or investigational therapies|Future or Investigational Therapies]] |
|
| |
|
| MUSTT randomized 704 patients with an EF < or = to 40%, NSVT and inducible VT/VF at EP study to arrhythmia therapy (medications and ICDs) or no antiarrhythmia. At 5 years there was a 27 risk reduction in mortality in the antiarrhythmia group. The relative risk of mortality when comparing ICD vs. no ICD was 0.24. There was no difference in mortality in the antiarrhythmic medication vs. no antiarrthymic medication subgroups.<ref>N Engl J Med. 1999 Dec 341:1882-1890.</ref>
| | ==Case Studies== |
|
| |
|
| SCD-HeFT randomized 2521 patients with class II or III CHF and EF < or = to 35% (ischemic or non ischemic) to three arms: 1. conventional therapy, 2. conventional therapy plus amiodarone, and 3. conventional therapy plus an ICD. After a median follow up of 46 months there was a relative risk of death of 0.77 in the ICD arm. Findings were similar in the ischemic and non-ischemic subgroups.<ref>N Engl J Med. 2005. Jan 352(3).</ref>
| | [[Dilated cardiomyopathy case study one|Case #1]] |
|
| |
|
| NYHA class IV heart failure is a contraindication to ICD placement.
| | ==Related Chapters== |
| | |
| ==Related chapters== | |
|
| |
|
| * [[Cardiomyopathy]] | | * [[Cardiomyopathy]] |
| * [[Hypertrophic cardiomyopathy]] | | * [[Hypertrophic cardiomyopathy]] |
| | * [[Stress cardiomyopathy]] |
| | * [[Anticoagulation in patients with dilated cardiomyopathy]] |
| | * [[First degree AV block]] |
| | * [[Second degree AV block]] |
| | * [[Beriberi heart disease]] |
|
| |
|
| ==Resources==
| |
| * [http://www.cardiomyopathy.org/html/which_card_dcm.htm Cardiomyopathy Association: Dilated cardiomyopathy]
| |
| * [http://www.childrenscardiomyopathy.org Children's Cardiomyopathy Foundation]
| |
|
| |
| ==References==
| |
| {{Reflist|2}}
| |
|
| |
| {{clr}}
| |
| {{Circulatory system pathology}} | | {{Circulatory system pathology}} |
|
| |
|
| Line 124: |
Line 60: |
| [[Category:Cardiomyopathy]] | | [[Category:Cardiomyopathy]] |
| [[Category:Cardiology]] | | [[Category:Cardiology]] |
| | | [[Category:Up-To-Date cardiology]] |
| | [[Category:Up-To-Date]] |
| {{WikiDoc Help Menu}} | | {{WikiDoc Help Menu}} |
| {{WikiDoc Sources}} | | {{WikiDoc Sources}} |
